Back to discover
Disease

Myeloproliferative Disorders

Late-stage therapeutic developmentEmerging researchRising momentum
MeSHMyeloproliferative Disorders
3
Publications
20
Clinical trials
2
Related conditions
2016
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 4 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Clinical Milestones5View
Results posted 1
Results expected 4
Activity timeline5

Clinical trials

16 sponsors · 1 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
20
All trials
6
Active
4
Late-stage
6
Completed
Late-stage studies

A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Phase 3 · Active, not recruiting · Celgene

Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia

Phase 2/3 · Completed · Roswell Park Cancer Institute

Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation

Phase 3 · Completed · Vanderbilt-Ingram Cancer Center

The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

Phase 3 · Completed · Alliance for Clinical Trials in Oncology
Recently completed

PEG IFN-alpha2a (Pegasys®) Therapy in Patients With Chronic Myeloproliferative Diseases (Excluding Philadelphia Chromosome Positive Chronic Myeloid Leukemia)

Phase 2 · Completed · M.D. Anderson Cancer Center

Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia

Phase 2/3 · Completed · Roswell Park Cancer Institute

Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients With Debilitating Hematologic Diseases

Phase 2 · Completed · National Heart, Lung, and Blood Institute (NHLBI)

Post Transplant Infusion of Allogeneic Cytokine Induced Killer Cells as Consolidative Therapy After Non-Myeloablative Allogeneic Transplantation in Patients With Myelodysplasia or Myeloproliferative Disorders

Phase 2 · Completed · Everett Meyer

Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation

Phase 3 · Completed · Vanderbilt-Ingram Cancer Center

The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

Phase 3 · Completed · Alliance for Clinical Trials in Oncology

Research activity

3 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
19902016
Major themes1
  • Philadelphia Chromosome1
Leading journals2
  • Blood2
  • Science (New York, N.Y.)1
Leading researchers8
  • Arber DA2
  • Bloomfield CD2
  • Borowitz MJ2
  • Le Beau MM2
  • Thiele J2
  • Vardiman JW2
  • Baltimore D1
  • Brunning RD1
Affiliations (unnormalised)6
  • University of Chicago2
  • Comprehensive Cancer Center1
  • Institute of Pathology1
  • John Hopkins Medical Institutions1
  • Massachusetts General Hospital1
  • Stanford University1

Related conditions

2 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Eosinophilia2Myelodysplastic Syndromes2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.

Identifiers
MeSHMyeloproliferative Disorders
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.